Clinical Trials in Mexico / NCT07149298
Active, not recruiting
Observational
Quality of Life In Patients With Allergic Conjunctivitis In Treatment With Sublingual Allergen Immunotherapy In A Referral Ophthalmological Hospital
NCT07149298 · tracked via the Priya Life Science Mexico tracker
Condition(s) studied
Allergic Conjunctivitis of Both Eyes
Study summary
The goal of this observational study is to evaluate both clinical changes and quality-of-life outcomes in patients with allergic conjunctivitis treated with allergen-specific immunotherapy, integrating objective clinical parameters and validated quality-of-life measures to obtain a comprehensive view of the therapeutic impact.
Eligibility
Inclusion Criteria:
* Patient records containing complete information
* Both sexes
* Age range: 6 to 86 years
* Between 2018 and 2023
* Diagnosed with allergic conjunctivitis
* Who have received treatment with allergen-specific sublingual immunotherapy
* With 8 assessments from the immunology and cornea department
* With 7 quality of life questionnaires completed by the patient
Exclusion Criteria:
* Patient records for other inflammatory ocular conditions
* Those with chronic diseases
* Those who have received naturopathic or immunomodulatory treatment during the follow-up period for allergen-specific sublingual immunotherapy
Primary outcome measure(s)
- Quality of life evaluated by the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Spanish version for Mexico in patients with Allergic Conjunctivitis treated with sublingual allergen immunotherapy. — Before Sublingual Immunotherapy
To evaluate the quality of life in patients with Allergic Conjunctivitis treated with sublingual allergen immunotherapy using the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Spanish version for Mexico. This questionnaire features 28 items grouped in 7 domains: activities, sleep, other symptoms, practical problems, nasal symptoms, eye symptoms, emotional. For each item, the minimum score is 0 and the maximum score is 6. After the questionnaire is completed, a mean score is calculated. A higher overall score indicates a poorer quality of life. - Quality of life in patients with Allergic Conjunctivitis treated with sublingual allergen immunotherapy evaluated using the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Spanish version for Mexico. — From enrollment to the end of the 6th month of Allergen Immunotherapy treatment
To evaluate the quality of life in patients with Allergic Conjunctivitis during 6 months of sublingual allergen immunotherapy using the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Spanish version for Mexico. This questionnaire features 28 items grouped in 7 domains: activities, sleep, other symptoms, practical problems, nasal symptoms, eye symptoms, emotional. For each item, the minimum score is 0 and the maximum score is 6. After the questionnaire is completed, a mean score is calculated. A higher overall score indicates a poorer quality of life. - Quality of life in patients with Allergic Conjunctivitis treated with sublingual allergen immunotherapy using Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Spanish version for Mexico. — From enrollment until 3 years of treatment with sublingual immunotherapy
To evaluate quality of life in patients with Allergic Conjunctivitis after completing allergen-specific sublingual immunotherapy using the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Spanish version for Mexico. This questionnaire features 28 items grouped in 7 domains: activities, sleep, other symptoms, practical problems, nasal symptoms, eye symptoms, emotional. For each item, the minimum score is 0 and the maximum score is 6. After the questionnaire is completed, a mean score is calculated. A higher overall score indicates a poorer quality of life.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Instituto de Oftalmología FAP Conde de Valenciana | Mexico City | Mexico |
More Instituto de Oftalmología Fundación Conde de Valenciana trials in Mexico
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07149298 on ClinicalTrials.gov ↗ ← All trials in Mexico